Dr. Reddy’s launches anti-viral drug in U.S.

Hyderabad, Dec 24, 2014

Dr. Reddy’s Laboratories on Tuesday said it had launched Valganciclovir tablets, an anti-viral drug in the U.S. market after receiving U.S. Food and Drug Administration (US FDA) approval.

The product is a therapeutic equivalent generic version of Valcyte made by Roche. A statement from the company said the Valcyte tablets brand has U.S. sales of around $440 million for the 12 month ending October, 2014, according to IMS data. Dr. Reddy’s Valganciclovir tablets in 450 mg strength is available in bottle counts of 60, the statement said. Earlier, the U.S. FDA had granted final approval to Dr. Reddy’s and U.S.-based Endo International to make cheaper copies of Valcyte. But the US FDA had stripped the company of its tentative approval to launch the copy of the drug. Business Line